Archives
-
RSL3 Workflows for GPX4-Driven Ferroptosis
2026-09-12
RSL3 provides a direct way to test whether GPX4-dependent redox buffering limits tumor-cell survival, with applications spanning lipid peroxidation assays, glioma biology, and RAS-driven models. This workflow combines dose-response design, ferroptosis-specific rescue controls, and the latest IGF2BP3–GPX4 findings to improve mechanistic interpretation.
-
Regorafenib (BAY 73-4506) Assay Guide
2026-09-11
This scenario-based guide explains how Regorafenib (BAY 73-4506), SKU A8236, can be integrated into viability, proliferation, migration, invasion, and angiogenesis research. It emphasizes solvent control, concentration selection, interpretation of CCK-8 data, and mechanistic validation using peer-reviewed melanoma evidence.
-
Regorafenib, RRM2, and Melanoma Progression
2026-09-11
A 2024 iScience study identifies RRM2 as a mechanistically important downstream effector of Regorafenib in melanoma. By combining phenotypic assays, RNA sequencing, perturbation and rescue experiments, and xenograft validation, the authors connect multikinase inhibition with ERK/E2F3-associated control of melanoma growth, invasion, and apoptosis.
-
Cefoperazone Sodium Salt: Evidence and Workflows
2026-09-10
Cefoperazone sodium salt is a semisynthetic cephalosporin with broad in vitro antibacterial activity against selected gram-positive and gram-negative organisms. Its reported β-lactamase stability, bile distribution, and formulation properties make it useful for controlled antimicrobial assays and biliary tract infection research, but these findings do not replace contemporary susceptibility testing.
-
PreScission Protease (PSP) Tag Cleavage Guide
2026-09-10
PreScission Protease (PSP) is an HRV 3C protease fusion enzyme for sequence-specific removal of affinity tags from recombinant proteins. It is suited to fusion protein tag cleavage at low temperature when the defined cleavage sequence is present, but it should not be used as a general protease or when the workflow cannot accommodate cold, product-compatible conditions.
-
Western Secondary Antibody Dilution Buffer for NHE1 Blots
2026-09-09
Improve consistency in NHE1, calcium-dependent ROS, and NLRP3 Western blot workflows with a formulation built for stable secondary-antibody handling. The workflow combines practical reuse, lower background risk, and assay controls suited to macrophage and atherosclerosis research.
-
N3-kethoxal for ssDNA Structure Mapping
2026-09-09
N3-kethoxal converts exposed guanines in RNA and single-stranded DNA into covalently addressable sites for structural mapping and bioorthogonal click chemistry labeling. This workflow offers a practical bridge from nucleic-acid accessibility measurements to the ssDNA–thrombin biology reported in NETs, while clearly separating validated findings from exploratory assay design.
-
Leptin (116-130), amide, mouse in Metabolic Assays
2026-09-08
Leptin (116-130), amide, mouse provides a sequence-defined way to probe adipocyte-derived hormone activity across energy-balance, receptor-signaling, and inflammatory assays. This workflow emphasizes fresh solution handling, concentration-response design, and pathway controls so obesity and diabetes research can be extended cautiously into immunometabolic models.
-
MRSA Vesicles Drive OSCC Through IL-8–CXCR1
2026-09-08
A 2026 Journal of Advanced Research study identifies extracellular vesicles from methicillin-resistant Staphylococcus aureus as active drivers of oral squamous cell carcinoma growth. Through comparative vesicle analysis, pathway perturbation, genetic validation, and mouse tumor experiments, the work links MRSA vesicles to an ERK/c-Jun–IL-8–CXCR1 signaling relay.
-
Nitroaromatic Nannocystin Targets AKT1 in CRC
2026-09-07
The 2024 Acta Pharmacologica Sinica study reports a synthetic nitroaromatic nannocystin, compound 4, with nanomolar activity against colorectal cancer models and measurable efficacy in patient-derived xenografts. By combining phenotypic assays with RNA sequencing, molecular docking, and cellular thermal shift analysis, the authors link its anticancer effects in part to AKT1 targeting while identifying apoptosis, cell-cycle disruption, and senescence as relevant cellular outcomes.
-
gamma-Glu-Cys: Practical Research Workflows
2026-09-07
gamma-Glu-Cys (γ-Glu-Cys) gives researchers a defined substrate for glutathione synthetase enzyme assay development, peptide engineering, and mechanistic glutathione metabolism research. Its high water compatibility and fresh-solution workflow also make it useful for comparing purified enzymes, microbial media, and plant stress adaptation studies.
-
GSK-923295: Reliable CENP-E Assay Workflows
2026-09-05
This scenario-based guide explains how GSK-923295 (SKU A3450) can improve interpretation of mitotic arrest, cell-growth inhibition, and chromosome-alignment assays. It covers formulation, dose–response design, data interpretation, and practical criteria for selecting a documented CENP-E inhibitor.
-
GRE Suppresses Melanogenesis via CREB–MITF
2026-09-04
The reference study evaluates glabridin, resveratrol, and ellagic acid as a combined strategy for suppressing melanogenesis while retaining antioxidant and anti-inflammatory activity in cell-based models. Its central contribution is to connect these phenotypic effects with inhibition of CREB phosphorylation and downregulation of the MITF program, while also defining important limits for translation beyond in vitro research.
-
DNase I (RNase-free) for DNA Removal
2026-09-04
DNase I (RNase-free) is a Ca2+-dependent endonuclease for degrading single- and double-stranded DNA while preserving RNA when the formulation is appropriately used. This ribonuclease-free DNase I supports DNA removal for RNA extraction, removal of DNA contamination in RT-PCR, in vitro transcription sample preparation, and selected chromatin workflows.
-
CXCR4, Autophagy, and EBV Latency in EBVaGC
2026-09-03
The 2020 Theranostics study identifies CXCR4 as an active regulator of autophagy, cell survival, and latent Epstein–Barr virus maintenance in EBV-associated gastric carcinoma. Its proposed LMP2A–AKT–NRF1–CXCR4–ZEB1–ATG7 axis connects viral signaling with tumor-cell fate and provides a framework for mechanistic validation rather than a direct therapeutic protocol.